You are here: Industry Insights > HAE

News List

MHRA allows HAE patients early access to berotralstat pharmatimes
November 04, 2020
Patients with hereditary angioedema (HAE) living in the UK will get early access to BioCryst's berotralstat before the drug is officially approved for this indication by the European Commission.
Shire's Takhzyro scores EU approval in rare genetic disorder hereditary angioedema pharmafile
December 04, 2018
Shire has announced that it has secured European approval for its subcutaneous injection Takhzyro (lanadelumab) for the routine prevention of attacks as a result of hereditary angioedema (HAE)...
Shire receives EU approval for Takhzyro pharmatimes
December 03, 2018
Takhzyro (lanadelumab) is a subcutaneous injection indicated for routine prevention of recurrent HAE attacks in patients aged 12 years and older.
Lanadelumab effective in reducing hereditary angioedema attacks europeanpharmaceuticalreview
November 30, 2018
Results of a clinical trial has led to the FDA approval of a monoclonal antibody drug called lanadelumab, to treat hereditary angioedema attacks…
Shire’s lanadelumab shown to significantly cut HAE attacks pharmatimes
November 19, 2018
Shire says it presented data showing that its experimental drug lanadelumab provides a significant and clinically meaningful reduction of hereditary angioedema (HAE) attacks.
Setback for Pharming’s bid to expand use of Ruconest pharmatimes
September 27, 2018
US regulators have turned down Pharming’s application to expand the approved uses of Ruconest to include prophylaxis...